Janssen-Cilag Pty

Company snapshot

Janssen-Cilag S.p.A is a pharma organization headquartered in SYDNEY, IT. Primary therapeutic focus areas include Dermatitis, Atopic, Cancer, Ulcerative Colitis. NovaPharmaNews links 3 clinical program(s), 19 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: approved (2), phase 3 (1).

• 26 approved product(s) across US/EU regulatory metadata.
• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Janssen-Cilag Pty. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Janssen-Cilag Pty.

1. Jun 8, 2026 Clinical update

   CNTO148UCO3003 — Phase 3

2. Jun 8, 2026 Clinical update

   Tramadol HCI/acetaminophen — Approved

3. May 26, 2026 Clinical update

   Tacrolimus — Approved

View all clinical trial activity →

• What is Janssen-Cilag Pty?

  Janssen-Cilag S.p.A is a pharma organization headquartered in SYDNEY, IT. Primary therapeutic focus areas include Dermatitis, Atopic, Cancer, Ulcerative Colitis. NovaPharmaNews links 3 clinical program(s), 19 drug profile(s), and 0 patent record(s) to this entity from public FDA,

• Is Janssen-Cilag Pty publicly traded?

  Janssen-Cilag Pty appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Janssen-Cilag Pty develop or market?

  We link 24 drug profile(s) where Janssen-Cilag Pty is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/janssen-cilag-international-nv#company-drugs.

• What are the latest developments for Janssen-Cilag Pty?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Janssen-Cilag Pty focus on?

  Janssen-Cilag Pty focuses on Dermatitis, Atopic, Cancer, Ulcerative Colitis based on our analysis of their pipeline programs and drug development activities.